Bausch Health Companies Inc. [BHC] stock Downgrade by BofA Securities analyst, price target now $27


Bausch Health Companies Inc. [NYSE: BHC] slipped around -0.72 points on Friday, while shares priced at $16.04 at the close of the session, down -4.30%. The company report on May 6, 2022 that Bausch Health Announces Thomas J. Appio As Chief Executive Officer.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


– Bausch Health Companies Inc. (NYSE/TSX: BHC) (Bausch Health) today announced its full leadership team and Board of Directors, including Chief Executive Officer (CEO) Thomas J. Appio.1 Upon completion of the initial public offering (IPO) of the Bausch + Lomb eye health business,2 former CEO Joseph C. Papa will assume the role of chairman and CEO of Bausch + Lomb.

“It is an honor and privilege to lead Bausch Health at this pivotal time in its history, and I am excited for our future,” said Mr. Appio. “We are a global specialty pharmaceutical company with deep expertise in gastroenterology, hepatology, neurology, dermatology and international pharmaceuticals serving patients for more than 60 years.”.

Bausch Health Companies Inc. stock is now -41.91% down from its year-to-date (YTD) trading value. BHC Stock saw the intraday high of $16.725 and lowest of $15.86 per share. The company’s 52-week high price is 32.54, which means current price is +1.13% above from all time high which was touched on 01/05/22.

Compared to the average trading volume of 4.29M shares, BHC reached a trading volume of 15372586 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Bausch Health Companies Inc. [BHC]?

BofA Securities have made an estimate for Bausch Health Companies Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on March 24, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price from $26 to $42. The new note on the price target was released on February 17, 2021, representing the official price target for Bausch Health Companies Inc. stock. Previously, the target price had yet another raise from $25 to $30, while Piper Sandler kept a Neutral rating on BHC stock.

The Average True Range (ATR) for Bausch Health Companies Inc. is set at 1.07, with the Price to Sales ratio for BHC stock in the period of the last 12 months amounting to 0.72. Price to Free Cash Flow for BHC in the course of the last twelve months was 5.24 with Quick ratio for the last quarter at 0.90.

How has BHC stock performed recently?

Bausch Health Companies Inc. [BHC] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.62. With this latest performance, BHC shares dropped by -30.35% in over the last four-week period, additionally sinking by -40.75% over the last 6 months – not to mention a drop of -42.88% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BHC stock in for the last two-week period is set at 18.07, with the RSI for the last a single of trading hit 11.04, and the three-weeks RSI is set at 23.78 for Bausch Health Companies Inc. [BHC]. The present Moving Average for the last 50 days of trading for this stock 22.13, while it was recorded at 17.68 for the last single week of trading, and 25.69 for the last 200 days.

Bausch Health Companies Inc. [BHC]: Deeper insight into the fundamentals

Bausch Health Companies Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.10.

Earnings analysis for Bausch Health Companies Inc. [BHC]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BHC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bausch Health Companies Inc. go to 8.70%.

Insider trade positions for Bausch Health Companies Inc. [BHC]

There are presently around $4,240 million, or 66.80% of BHC stock, in the hands of institutional investors. The top three institutional holders of BHC stocks are: ICAHN CARL C with ownership of 34,721,118, which is approximately 1.794% of the company’s market cap and around 2.30% of the total institutional ownership; PAULSON & CO. INC., holding 25,839,035 shares of the stock with an approximate value of $414.46 million in BHC stocks shares; and NOMURA HOLDINGS INC, currently with $304.6 million in BHC stock with ownership of nearly 23.485% of the company’s market capitalization.

184 institutional holders increased their position in Bausch Health Companies Inc. [NYSE:BHC] by around 29,827,097 shares. Additionally, 159 investors decreased positions by around 22,028,003 shares, while 85 investors held positions by with 212,509,898 shares. The mentioned changes placed institutional holdings at 264,364,998 shares, according to the latest SEC report filing. BHC stock had 81 new institutional investments in for a total of 12,814,219 shares, while 46 institutional investors sold positions of 5,373,664 shares during the same period.